OMER vs TRNS Comparison

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Transcat Inc is involved in providing calibration and laboratory instrument services and the distribution of test, measurement, and control instrumentation. The product and services portfolio of the company consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, and others. The firm has Service and Distribution operating segments. The company derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Extech, FLIR, Fluke, Keysight, Megger, and others.